Clinical trials: Massive Pulmonary Embolism
PE - Pulmonary Embolism, PE - Pulmonary Thromboembolism
FlowTriever for Acute Massive Pulmonary Embolism (FLAME)
To evaluate treatment outcomes of patients diagnosed with high-risk (massive) pulmonary embolism
- Trial name
- FLAME (NCT04795167)
- Where
- 11 sites in United States
- Volunteers
- 115 people
- Sponsor
- Inari Medical
Pulmonary Embolism, Pulmonary Embolism Acute Massive
Registry of Catheter Intervention in Pulmonary Embolism
Multicenter longitudinal observational ambispective (retrospective cases from 2014 and prospective from 2018 onwards) cohort study.
- Conditions
- Pulmonary Embolism, Pulmonary Embolism Acute Massive, Pulmonary Embolism Acute, Pulmonary Embolism and Thrombosis
- Trial name
- RiTEP (NCT06348459)
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Hospital San Carlos, Madrid
Pulmonary Embolism Subacute Massive
Artificial Intelligence to StrategiCally Enhance Pulmonary Embolism Response Team Activation
Pulmonary embolism (PE) remains a high mortality and morbidity disease state. The investigators have previously shown that use of a Pulmonary Embolism Response Team (PERT) can improve overall readmission, bleeding, and mortality…
- Trial name
- ASCENT (NCT06246045)
- Testing
- Walking test
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Right Ventricular Failure, Pulmonary Embolism
Quantitative Assessment of RV Strain Using cMRI Following Catheter Intervention on PE
Acute pulmonary embolism (PE) is a condition in which the vessels carrying blood to the lungs become suddenly blocked, usually by a blood clot.
- Trial name
- RVEF (NCT03341208)
- Testing
- Cardiac Magnetic Resonance Imaging
- Volunteers
- 10 people
- Sponsor
- University of Arizona
Pulmonary Embolism, Acute Pulmonary Embolism
Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy
The purpose of this study is to determine if the EKOS EkoSonic® Endovascular Device when used in conjunction with recombinant tissue plasminogen activator (t-PA) as a treatment for acute PE will decrease the ratio of right…
- Conditions
- Pulmonary Embolism, Acute Pulmonary Embolism, Sub-massive Pulmonary Embolism, Massive Pulmonary Embolism
- Trial name
- SEATTLE II (NCT01513759)
- Testing
- recombinant tissue plasminogen activator, EKOS EkoSonic Endovascular System
- Where
- 22 sites in United States
- Volunteers
- 150 people
- Sponsor
- Boston Scientific Corporation
Pulmonary Embolism Subacute Massive
Catheter Directed Therapy in Intermediate Risk Pulmonary Embolism Patients
Aim of the work: 1. To compare conventional medical therapy versus catheter-directed therapy in intermediate high risk acute pulmonary embolism. 2.
- Trial name
- NCT05612854
- Testing
- Mechanical embolectomy: by hydromechanical defragmentation by pigtail, Suction embolectomy by the Penumbra Indigo aspiration system
- Volunteers
- 200 people
- Sponsor
- Assiut University
Angiographically Confirmed Acute Massive Pulmonary Embolism Treated With Endovascular Mechanical Fragmentation and Thrombolytic Therapy
Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy
A prospective randomised controlled study to evaluate outcomes of the treatment with pradaxa or warfarin for prevention of recurrent DVT in patients with angiographically confirmed acute massive pulmonary embolism undergoIng…
- Trial name
- Re-Spire (NCT02979561)
- Testing
- Dabigatran Etexilate, Warfarin
- Where
- Russia
- Volunteers
- 200 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Pulmonary Embolism, Pulmonary Thromboembolism
Recombinant Streptokinase Versus Urokinase in Pulmonary Embolism in China (RESUPEC)
Recombinant streptokinase (r-SK) is an effective thrombolytic agent developed with gene engineering. Its characteristics of high output and low production cost make it affordable in treating acute myocardial infarction (AMI) in…
- Trial name
- RESUPEC (NCT00968929)
- Testing
- Recombinant Streptokinase, Urokinase
- Where
- 8 sites in China
- Volunteers
- 83 people
- Sponsor
- Beijing Chao Yang Hospital
Pulmonary Embolism, Pulmonary Embolism Subacute Massive
Effect of iNO in Patients With Submassive and Massive PE
A single center study to evaluate the effect of inhaled nitric oxide (iNO) on pulmonary dynamics in patients presenting with imaging confirmed intermediate/submassive or massive pulmonary embolism (PE).
- Trial name
- NCT04996667
- Testing
- inhaled nitric oxide (iNO)
- Where
- United States
- Sponsor
- University of California, Los Angeles
Pulmonary Embolism Subacute Massive, Complication of Treatment
Safe Delivery of Thrombolytic Treatment for Pulmonary Embolism Using ClotPro® Viscoelastic Tests
The aim of this work was to reduce the bleeding risk during thrombolysis using the viscoelastic blood coagulation tests.
- Conditions
- Pulmonary Embolism Subacute Massive, Complication of Treatment, Fibrinolysis; Hemorrhage
- Trial name
- NCT06667882
- Testing
- Alteplase Injectable Product
- Where
- Hungary
- Volunteers
- 33 people
- Sponsor
- Semmelweis University
Pulmonary Embolism
Catheter Thrombectomy in Patients With Massive Pulmonary Embolism
Official Title: Compassionate Use of Catheter Thrombectomy (Aspirex 11F) in Patients With Massive Pulmonary Embolism Study Population: Patients >/= 18 years of age with massive pulmonary embolism suitable for mechanical…
- Trial name
- NCT00314002
- Testing
- Mechanical Thrombectomy
- Where
- 5 sites in Germany, Switzerland
- Volunteers
- 50 people
- Sponsor
- Straub Medical AG
Pulmonary Embolism, Acute Pulmonary Embolism
FlowTriever Pulmonary Embolectomy Clinical Study
Evaluate the safety and effectiveness of the FlowTriever System for use in the removal of emboli from the pulmonary arteries in the treatment of acute pulmonary embolism.
- Conditions
- Pulmonary Embolism, Acute Pulmonary Embolism, Submassive Pulmonary Embolism, Massive Pulmonary Embolism
- Trial name
- FLARE (NCT02692586)
- Testing
- FlowTriever System
- Where
- 18 sites in United States
- Volunteers
- 106 people
- Sponsor
- Inari Medical
Trauma
Pragmatic, Randomized Optimal Platelet and Plasma Ratios
Pragmatic, Randomized, Optimal Platelet and Plasma Ratios (PROPPR)is a Phase III trial designed to evaluate the difference in 24-hour and 30-day mortality among subjects predicted to receive massive transfusion ([MT] (defined as…
- Trial name
- PROPPR (NCT01545232)
- Testing
- 1:1:1 Blood Transfusion Ratio, 1:1:2 Blood Transfusion Ratio
- Where
- 12 sites in United States, Canada
- Volunteers
- 680 people
- Sponsor
- The University of Texas Health Science Center, Houston
Pulmonary Embolism
DS-9231 in Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)
The primary objective of this study is to evaluate safety and initial effectiveness of DS-9231 when taken together with current standard of care.
- Trial name
- NCT03316729
- Testing
- DS-9231
- Sponsor
- Daiichi Sankyo
Massive Pulmonary Embolism
Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase FORPE
Objective: to evaluate the efficacy and safety of the Recombinant Non-immunogenic Staphylokinase with its single bolus administration in comparison with the bolus-infusion administration of the Alteplase in patients with massive…
- Trial name
- NCT04688320
- Testing
- Recombinant nonimmunogenic staphylokinase, Alteplase
- Where
- 23 sites in Russia
- Volunteers
- 310 people
- Sponsor
- Supergene, LLC
Pulmonary Embolism
Surgery in Pulmonary Embolisms
Measure early out comes of surgical pulmonary embolectomy in patients with massive and sub massive pulmonary embolism.
- Trial name
- NCT06070129
- Testing
- surgical pulmonary embolectomy
- Volunteers
- 15 people
- Sponsor
- Assiut University
Pulmonary Embolism, Pulmonary Embolus/Emboli
Non-Invasive Measurement of Cardiac Output and Stroke Volume in PE
Pulmonary embolism impacts over 1 in 1000 adults annually and is the third leading cause of cardiovascular death after heart attack and stroke. The consequence of each PE is widely variable.
- Conditions
- Pulmonary Embolism, Pulmonary Embolus/Emboli, Pulmonary Disease, Pulmonary Embolism and Thrombosis
- Trial name
- NCT04855370
- Testing
- Non-invasive hemodynamic measurements
- Where
- United States
- Sponsor
- University of California, Los Angeles
Heart Failure, Cardiomyopathies
Multimodal Physiologic State Intelligence Study
The OMNIPHYS study will investigate whether multimodal ultrasound and other routinely collected clinical and physiologic data can be combined with artificial intelligence to characterize changes in a person's physiologic state…
- Conditions
- Heart Failure, Cardiomyopathies, Pulmonary Hypertension, Myocarditis; Acute or Subacute
- Trial name
- OMNIPHYS (NCT07814118)
- Testing
- OMNIPHYS Multimodal Ultrasound Imaging System
- Where
- United States
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Truway Health, Inc.
Pulmonary Embolism
Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial
Phase II trial of TS23
- Trial name
- NAIL-IT (NCT05408546)
- Testing
- TS23
- Where
- 13 sites in United States
- Volunteers
- 64 people
- Sponsor
- Translational Sciences, Inc.
Pulmonary Embolism
Low Dose Prolonged Infusion of Tissue Type Plasminogen Activator Therapy in Massive Pulmonary Embolism
The aim of the present study was to assess the effects of low-dose (25mg) prolonged administration (in 6 hours) of tissue type plasminogen activator (tPA) on in-hospital mortality and outcomes in patients with massive PE.
- Trial name
- NCT02029456
- Testing
- 25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Ahi Evren Chest and Cardiovascular Surgery Education and Research Hospital